{
    "nctId": "NCT03740945",
    "briefTitle": "Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer",
    "officialTitle": "Effect of Intravaginal Prasterone (DHEA) on Moderate to Severe Symptoms of Vulvovaginal Atrophy Due to Menopause, in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer - (Placebo-Controlled, Double Blind and Randomized Phase III Study)",
    "overallStatus": "WITHDRAWN",
    "conditions": "Vaginal Atrophy in Breast Cancer Patients",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Change from Baseline to Week 12 in the Percentage of Superficial Cells",
    "eligibilityCriteria": "Inclusion Criteria:\n\nMain criteria:\n\n1. Natural, surgically- or treatment-induced postmenopausal women (non hysterectomized or hysterectomized) with breast cancer (stage 1 or 2) who is currently under treatment with an aromatase inhibitor and will remain on that treatment for the duration of the study.\n2. Women between 30 and 80 years of age\n3. Women having \u22645% of superficial cells on vaginal smear at baseline\n4. Women having a vaginal pH above 5 at baseline\n5. Women who have self-identified moderate or severe symptom(s) of vaginal atrophy\n\nExclusion Criteria:\n\nMain criteria:\n\n1. Clinically significant metabolic or endocrine disease (including diabetes mellitus) not controlled by medication\n2. The administration of any investigational drug within 30 days of screening visit",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}